(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Eledon Pharmaceuticals's earnings in 2026 is -$87,713,000.On average, 7 Wall Street analysts forecast ELDN's earnings for 2026 to be -$81,841,462, with the lowest ELDN earnings forecast at -$86,081,339, and the highest ELDN earnings forecast at -$68,285,678. On average, 6 Wall Street analysts forecast ELDN's earnings for 2027 to be -$71,503,593, with the lowest ELDN earnings forecast at -$83,598,224, and the highest ELDN earnings forecast at -$59,417,408.
In 2028, ELDN is forecast to generate -$74,307,655 in earnings, with the lowest earnings forecast at -$91,875,276 and the highest earnings forecast at -$60,304,235.